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Abstract
Introduction: The apolipoprotein E (APOE) genotype is the strongest genetic risk factor
for late-onset Alzheimer’s disease. However, its effect on lipid metabolic pathways, and
their mediating effect on disease risk, is poorly understood.
Methods: We performed lipidomic analysis on three independent cohorts (the Australian Imaging, Biomarkers and Lifestyle [AIBL] flagship study, n = 1087; the
Alzheimer’s Disease Neuroimaging Initiative [ADNI] 1 study, n = 819; and the Busselton Health Study [BHS], n = 4384), and we defined associations between APOE ε2 and
ε4 and 569 plasma/serum lipid species. Mediation analysis defined the proportion of
the treatment effect of the APOE genotype mediated by plasma/serum lipid species.
Results: A total of 237 and 104 lipid species were associated with APOE ε2 and ε4,
respectively. Of these 68 (ε2) and 24 (ε4) were associated with prevalent Alzheimer’s
disease. Individual lipid species or lipidomic models of APOE genotypes mediated up to
30% and 10% of APOE ε2 and ε4 treatment effect, respectively.
Discussion: Plasma lipid species mediate the treatment effect of APOE genotypes on
Alzheimer’s disease and as such represent a potential therapeutic target.
KEYWORDS

APOE ε2, APOE ε4, Alzheimer’s disease, lipidomics, lipid species, mass spectrometry

PART 1–NARRATIVE

1.1

The apolipoprotein E (APOE) gene is by far the largest genetic
risk factor for sporadic Alzheimer’s disease

(AD).1,2

Current state of knowledge

Because amyloid beta (Aβ) is central to many hypotheses in both famil-

Despite its

ial and sporadic AD pathogenesis, the relationship between APOE

identification and characterization nearly three decades ago, the

and sporadic AD has been largely investigated in the context of

mechanism by which the gene it influences sporadic AD onset and

Aβ accumulation and clearance. Multiple studies have demonstrated

progression remains to be fully determined. There are two alleles

a high proportion of brain Aβ in healthy ε4-positive individuals rel-

of interest: the ε4 allele dramatically increases risk for sporadic

ative to the other alleles,3,4 with supporting evidence in human

AD, whereas the ε2 allele provides protection or resilience. The

stem-cell–derived neuronal studies highlighting increased Aβ pro-

encoded protein (apolipoprotein E [apoE]) is involved in lipoprotein

duction with the ε4 allele.5,6 In vitro studies have indicated indi-

transport and metabolism. In peripheral circulation, apoE associates

rect roles for APOE in Aβ clearance via interaction with microglia7

with triglyceride-rich lipoprotein particles (chylomicrons and very

and other neuronal cells.8 Despite evidence of the involvement of

low-density lipoprotein). Despite its annotation as a causal genetic

APOE with Aβ, no clear mechanism has been identified. Because ther-

variant of sporadic AD, defining the underlying mechanism and the

apeutics targeted toward Aβ have largely been unsuccessful, it is

therapeutic potential remain elusive and are topics of considerable

likely that several underlying pathways are involved in sporadic AD

interest.

development.
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As a key constituent of lipoproteins and lipid transport, a logical
role for APOE variants in sporadic AD development would be through

RESEARCH IN CONTEXT

perturbations to lipid metabolism. The direct effect of APOE vari1. Systematic Review: The authors reviewed the literature

ants on human peripheral lipoprotein metabolism has been examined
intensively.9–12 Comprehensive Nuclear Magnetic Resonance (NMR)

using PubMed and Google to identify recent reports of

lipoprotein profiling shows that APOE ε4 leads to minor increases in

the risk factors for Alzheimer’s disease (AD) and the

nearly all lipoprotein subclasses, whereas APOE ε2 results in stronger

risk associated with the apolipoprotein E (APOE) geno-

changes to the lipoprotein

profile.13

types. Although the relationship between APOE geno-

In the central nervous system,

types and lipoprotein levels has been reported previously,

apoE is the most abundant lipoprotein, playing an important role in

no reports on the relationship with the underlying lipid

lipid transport and cholesterol homeostasis.14 Although lipoproteins

metabolism were found.

are the main carriers of lipids and are studied more extensively in the

2. Interpretation: We report detailed associations between

context of AD, it has been proposed that lipid metabolism— repre-

APOE genotypes and plasma lipid species, indicating an

sented by the complex lipid metabolic pathways responsible for the

effect on lipid metabolism. The APOE ε2 allele showed

synthesis, interconversion, and catabolism of the small amphiphilic

stronger associations with ether lipid species than the

molecules that make up lipoprotein particles in addition to cellular membranes—plays a more critical role in AD

APOE ε4 allele, with these lipid species mediating up to

pathogenesis.15,16

30% of APOE ε2 treatment effect, leading to increased

The effects of APOE variants appear to mildly alter the relation-

resilience.

ship between peripheral lipid metabolites and the strength of asso-

3. Future Directions: Understanding the relationship

ciation with AD.17,18 These findings collectively support a poten-

between ether lipid metabolism, AD risk and resilience

tial relationship between lipid metabolism, APOE genotypes, and

presents new therapeutic options to delay or prevent the

AD risk.

onset of disease.

1.2
Knowledge gap, the study approach, and
other alternatives
1.3

Findings

Sporadic AD is a complex disease unique to the human population, evident only through our relatively long life-span and higher cognitive

The mechanism by which APOE genotypes modulate risk has yet to

function. Thus studies in human populations are important and nec-

be fully elucidated, and thus identifying this could pave way for addi-

essary to understand the complex relationships that exist. Lipidomics

tional modulatory therapeutic targets. We summarize the main find-

is a specialized field examining lipid metabolites in biological systems,

ings into three major categories. (1) We identified multiple associations

and it has typically been limited to small sample sizes. Recent advances

with specific lipid classes and species that were independent of clinical

have paved the way for population-level approaches that provide the

lipoprotein measurements, (2) we identified age-specific interactions

power to examine associations within the variability of human diver-

between the associations of lipid species and APOE genotypes, and (3)

sity. Owing to the lack of large human studies conducted in the field,

we demonstrated that lipid species partially mediate the AD risk result-

the associations between APOE genotypes, circulating lipid metabo-

ing from inherited APOE genotypes.

lites, and the relationship with sporadic AD risk have not been examined in detail.
To address this gap in knowledge, we examined the associations between plasma lipid species and APOE genotypes in three

1.4
Lipid metabolites are strongly associated with
APOE genotype

large cohorts comprising the Busselton Health Study (BHS), the
Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study,

We noted that APOE genotypes were associated with circulating

and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 1 study.

lipoprotein levels in all three cohorts only in healthy individuals, in par-

The associations were determined independent of disease using

ticular, higher high-density lipoprotein cholesterol (HDL-C) and lower

the BHS, a largely healthy population cohort from Australia, to

total cholesterol were evident in individuals with the APOE ε2 allele

avoid reverse causation. Associations with APOE were then con-

(Table 1). These associations have been observed previously9–12,19,20

trasted to lipid associations observed with prevalent AD. Finally,

and highlight the importance of considering clinical lipids when examin-

mediation analyses using individual lipid species or combined APOE

ing lipidomic associations. Without adjusting for clinical lipids, associa-

lipid summary scores were performed to assess the role of lipid

tions with lipid species were influenced by the relative levels of lipopro-

metabolism in mediating risk of APOE ε2 and ε4 alleles on AD

teins in circulation. However, after adjustment for clinical lipids, the

(Figure 1).

resulting associations highlight altered lipid species composition as a

4
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F I G U R E 1 Study design. In this study, the analyses include three main sections: the identification of the significant associations of lipid species
with the apolipoprotein E(APOE) gene and prevalent Alzheimer’s disease (AD) (A), the improvement of the power of the associations by
meta-analysis combining Australian Imaging, Biomarkers and Lifestyle (AIBL) and Alzheimer’s Disease Neuroimaging Initiative (ADNI) (B), and the
causality inference of APOE genotypes to prevalent AD through lipid species by mediation analysis (C). (A) For each participant, we utilized
available samples at their last acquired time point (n = 1087) to maximize the number of participants in the association studies. Lipid association
studies with APOE were performed using only the control (CN) subset, whereas associations with AD prevalence was examined between the
control and AD subsets. Covariates fitted into the models included age, sex, and BMI. Models for ADNI included fasting status, whereas models for
AIBL included sample time point. To identify associations that were independent of lipoprotein metabolism, a second set of analyses was
performed with further adjustment for clinical lipids (total cholesterol, HDL-C, and triglycerides). Associations were corrected for multiple
comparisons using the method of Benjamini Hochberg (BH).60 In the Busselton Health Study (BHS), interaction of APOE genotypes and age was
examined using a binary cut-off of 60 years (Table S6). The “±clinical lipids” means the linear regression was performed separately with/without
clinical lipids adjustment. (B) Associations between APOE genotypes and lipid species and the associations between AD prevalence and lipid
species were analyzed using a fixed-effect inverse-variance weighted meta-analysis. Heterogeneity between AIBL and ADNI was assessed using
Cochran Q. (C) The mediation analysis was performed on the combined AIBL and ADNI data sets, treating AD as the outcome and APOE genotypes
as the treatment. There were two types of mediators: (1) individual lipid species (that showed concordant associations with APOE and AD from the
previous analyze) and (2) APOE lipid scores. The lipid scores were created by ridge regression using either the lipid species concordant in
association with AD/APOE or all the lipid species to predict APOE ε2/ε4. The models were trained on either the BHS cohort (n = 4384) or the
combined AIBL and ADNI cohorts (Control; n = 900), followed with an external validation on the whole population of combined AIBL and ADNI
cohorts (n = 1597). The resulting predicted values on the validate set were the APOE lipid scores that were treated as mediators for the mediation
analysis
potential effect of APOE genotype. Of note, APOE ε2 exhibited stronger

cordant lipid species, nominally significant in both analyses, including

associations with the plasma lipidome than the APOE ε4 .

species of 18 lipid classes including ceramide, hexosylceramide, sphin-

In the BHS study, we observed 29 lipid classes and 347 lipid species

gomyelin, plasmalogens, alkyldiacylglycerol, and cholesteryl esters.

significantly associated with APOE ε2 after correction for multiple com-

Fewer significant associations with APOE ε4 were observed in both

parisons (Figure 2; Tables S1 and S2). Adjustment for clinical lipids, to

the BHS and meta-analysis of the AIBL and ADNI cohorts. There were

identify associations independent of lipoprotein metabolism, resulted

23 lipid classes and 223 lipid species significantly associated with APOE

in 28 lipids classes and 237 lipid species significantly associated. There

ε4 in BHS, after correction for multiple comparisons (Figure S1; Tables

were 20 classes and 133 species associated with APOE ε2 in the meta-

S3 and S4). When we further adjusted for clinical lipids, we observed

analysis of the fully adjusted AIBL and ADNI models (including healthy

18 lipid classes and 104 lipid species significantly associated with

individuals only). Comparison of the two analyses identified 120 con-

APOE ε4, after correction for multiple comparisons (Figure 2, Tables

5
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TA B L E 1 Basic characteristics of participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study, Alzheimer’s Disease
Neuroimaging Initiative (ADNI), and the Busselton Health Study (BHS)
AIBL
Number of APOE ε2 alleles

Number of APOE ε4 alleles

0

1

2

N

564

124

5

Age (years)

75.2 (6.5)

75.5 (6.9)

75.4 (5.2)

Gender (% female)

327 (58.0)

77 (62.1)

4 (80.0)

26.30(4.4)

26.3 (4.4)

2

BMI (kg/m )

P value

0

1

2

520

163

10

P-value

.927

75.7 (6.7)

74.2 (5.8)

71.6 (6.2)

.01

.44

303 (58.3)

100 (61.3)

5 (50.0)

.665

25.6 (5.1)

.927

26.3 (4.2)

26.3 (4.8)

26.6 (4.2)

.966

HDL-C (mmol/L)

1.56 (0.41)

1.67 (0.47)

1.58 (0.54)

.029

1.58 (0.43)

1.56 (0.42)

1.68 (0.46)

.656

Total Cholesterol (mmol/L)

5.28 (1.12)

5.15 (1.05)

5.52 (2.41)

.444

5.23 (1.11)

5.35 (1.16)

5.51 (0.94)

.4

Triglycerides (mmol/L)

1.27 (0.61)

1.19 (0.54)

2.30 (2.42)

.001

1.25 (0.63)

1.32 (0.65)

1.15 (0.46)

.4

1

37 (6.6)

8 (6.5)

0 (0.0)

38 (7.3)

7 (4.3)

0 (0.0)

2

57 (10.1)

15 (12.1)

1 (20.0)

55 (10.6)

17 (10.4)

1 (10.0)

3

28 (5.0)

5 (4.0)

0 (0.0)

23 (4.4)

10 (6.1)

0 (0.0)

4

63 (11.2)

9 (7.3)

0 (0.0)

53 (10.2)

17 (10.4)

2 (20.0)

5

379 (67.2)

87 (70.2)

4 (80.0)

351 (67.5)

112 (68.7)

7 (70.0)

N

174

31

2

152

50

5

Age (years)

75.8 (4.8)

75.2 (5.6)

73.5 (4.7)

75.7 (5.0)

76.0 (5.0)

74.6 (3.8)

ADNI

.661

.812

Gender (%female)

82 (47.1)

19 (61.3)

0 (0.0)

.133

76 (50.0)

23 (46.0)

2 (40.0)

.819

BMI (kg/m2 )

26.8 (4.4)

26.5 (4.0)

28.5 (1.2)

.782

27.2 (4.5)

25.8 (3.9)

24.8 (2.3)

.087

HDL-C (mmol/L)

1.36 (0.43)

1.43 (0.58)

1.32 (0.44)

.73

1.39 (0.44)

1.35 (0.49)

1.24 (0.44)

.693

Cholesterol (mmol/L)

4.74 (0.93)

4.76 (0.95)

3.37 (1.23)

.119

4.72 (0.94)

4.81 (0.96)

4.37 (0.66)

.566

Triglycerides (mmol/L)

1.42 (0.76)

1.54 (1.06)

0.93 (0.54)

.516

1.37 (0.68)

1.61 (1.11)

1.36 (0.64)

.19

Fasting status (% fasting)

16 (9.2)

3 (9.7)

0 (0.0)

.9

17 (11.2)

0 (0.0)

2 (40.0)

.003

N

3625

733

26

3221

1061

102

Age (years)

50.4 (17.3)

50.7 (17.6)

50.7 (16.7)

.9

50.67 (17.5)

50.2 (17.0)

47.9 (17.0)

.228

Gender (% female)

2032 (56.1)

413 (56.3)

16 (61.5)

.848

1836 (57.0)

572 (53.9)

53 (52.0)

.147

26.0 (4.2)

26.1 (4.2)

25.6 (4.3)

.844

26.0 (4.2)

26.0 (4.2)

25.4 (4.0)

.315

BHS

2

BMI (kg/m )
HDL-C (mmol/L)

1.38 (0.39)

1.44 (0.41)

1.45 (0.40)

.001

1.40 (0.39)

1.37 (0.40)

1.32 (0.37)

.024

Cholesterol (mmol/L)

5.65 (1.10)

5.26 (1.10)

4.37 (1.14)

<.001

5.52 (1.12)

5.74 (1.08)

5.65 (1.09)

<.001

Triglycerides(mmol/L)

1.29 (0.91)

1.34 (0.90)

1.38 (1.01)

.43

1.28 (0.89)

1.38 (0.91)

1.33 (1.25)

.009

*In this study, we only used the records at the last time point in AIBL cohort.

S3 and S4). Meta-analysis of the fully adjusted models in the AIBL

ferences from the larger sample size. Owing to the larger age range

and ADNI cohorts identified three lipid species associated with APOE

of the BHS compared to the AIBL and ADNI cohorts, we hypothe-

ε4, after correction, and 91 lipid species that were nominally signifi-

sized that age might influence how APOE genotype associates with

cant, of which 43 species were also nominally significant in the BHS

plasma lipids. Interaction analysis with a binary cut-off at age 60

cohort.

using the BHS cohort (age <60, n = 2884; age ≥ 60, n = 1368;
Tables S5) identified a nominal significant interaction of age with the
association of APOE ε2 with 48 lipid species from 12 classes (Fig-

1.5
APOE lipid associations are weaker with
increasing age

ure 3, Table S6). A greater number of the associations of APOE ε4
with lipid species were observed to have interaction effects of age
(88 lipid species from 18 classes; Figure 4, Table S7). These included

We observed stronger associations within the BHS cohort than the

species of phosphatidylethanolamine, alkylphosphatidylethanolamine,

AIBL and ADNI combined meta-analysis, beyond the expected dif-

alkenylphosphatidylethanolamine, and lysophosphatidylethanolamine

6
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F I G U R E 2 Association of APOE ε4 (A) and APOE ε2 (B) with lipid species in the Australian imaging, Biomarkers and Lifestyle (AIBL); Alzheimer’s
Disease Neuroimaging Initiative (ADNI); and Busselton Health Study (BHS) cohorts. ***Linear regression analyses of APOE ε4/ε2 against lipid
species were performed adjusting for age, sex, BMI, total cholesterol, HDL-C, triglycerides, timepoint (specific for AIBL), and fasting status (specific
for ADNI). Meta-analyses were performed by combining AIBL and ADNI data. Gray open circles, corrected P > .05; gray closed circles, corrected
P < .05; blue circles, top 10 species ranked by P-value; orange diamonds, lipid classes

Of interest, these results highlight the amelioration of the geno-

APOE ε4 associations were determined with healthy controls only,

type effect in the older group (≥60), particularly for the phos-

a survivorship bias may result a reduction in the strength of the

phatidylethanolamine classes that show a strong association with

associations between APOE ε4 genotype and plasma lipids with increas-

AD.16,17 This coincides with observations in the healthy AIBL and ADNI

ing age.

population where lipid associations with the APOE genotype, particularly the ε4 allele, were weaker. The large meta-analysis conducted
by Farrer et al., described a similar age–APOE relationship, where the
risk of AD from ε4 allele was considerably reduced at ages > 65 to

1.6
APOE ε2 resilience to AD is mediated via the
peripheral lipidome

70.1 Although the exact mechanism behind the reduced association
with increasing age remains to be determined, one possibility is that

Ether lipids showed concordant risk profiles for APOE genotype

individuals who ultimately maintain the lower level of ether lipids

and AD. Ether lipid associations with AD have been reported

progress to develop MCI, AD, or possibly other metabolic diseases

previously,23–25 also within the AIBL and ADNI studies.16,26 Some

including cardiovascular disease, where plasmalogens have shown

studies have suggested that these lipids confer protection and may

a negative

association,21,22

leading to a survivorship bias. Because

become depleted in disease progression (see reviews27–29 ). Species

7
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F I G U R E 3 Interaction of age on the associations of APOE ε2 with peripheral lipid species. Linear regression analyses of APOE ε2 against lipid
species, adjusted for APOE ε4, age, sex, BMI, total cholesterol, HDL-C, and triglycerides with the interaction terms of age (binary cut-off at
60-years-old, Panel A) was performed in the Busselton Health Study (BHS) cohort. Beta coefficients and 95% CI for each group were plotted (left
panels). Beta coefficients and 95% CI for lipid species showing significant interaction (P value < .05) are plotted together (right panel)

from the ether lipid group are structurally different from other lipids

risk by peripheral lipid species or lipid scores was much lower for the

species by having the characteristic fatty alcohol instead of a carboxylic

APOE ε4 allele (Table 2; Figure S2; Table S12). These mediation analy-

acid in the sn1 position of the glycerol backbone. Plasmalogens are a

ses strengthen the evidence for the involvement of ether lipids in AD

subclass of ether lipids, with the characteristic vinyl-ether bond link-

etiology. Because lipids constitute modifiable risk factors, and dietary

ing the alcohol to the glycerol backbone. These lipids are peroxisome-

supplements are available to increase circulating ether lipids in

dependent species that have been highly implicated in AD.

humans,27 this raises the possibility of risk reduction through ether

Here we demonstrate that ether lipids, in particular, are lower in

lipid modulation.

individuals with the APOE ε4 allele, and higher in individuals with the

Alkyl diacylglycerols is notable owing to its ether-linkage in the sn1

APOE ε2 allele, independent of changes in circulating lipoprotein lev-

position (with fatty acyl linkages in the sn2 and sn3 positions), placing

els. Furthermore, the same lipid species were associated with AD (Fig-

them in the same family as ether lipids and plasmalogens, a lipid class

ure 5; Tables S8-S10). In mediation analyses, we observed that up to

reported to be negatively associated with AD.16,23,30,31 Although the

36% of the AD risk from APOE ε2 was mediated through peripheral lipid

biosynthetic origin of the alkyldiacylglycerols in the periphery remains

species, notably the alkyldiacylglycerol and plasmalogens species, with

largely uncharacterized, it is clear that they are derived from the per-

TG (O-52:2) [NL-16:0] showing the strongest mediation effect (Fig-

oxisomal pathway that synthesizes 1-O-alkyl-dihydroxyacetone phos-

ure S2, Table S11), whereas lipid scores created against AD mediated

phate, which is then converted into 1-O-alkyl-2-acylglycerol in the

up to 24% the AD risk from APOE ε2 (Table 2). This mediation of AD

endoplasmic reticulum, at which point it can be converted into either

(0.09 - 0.52)

−0.10

0.24

Prop. mediated

(0.15 - 0.21)

(0.02 - 0.11)

0.18

0.06

ADE (Avg)

Prop. mediated

(Avg)

(0 - 0.02)

0.01

(0.03 - 0.13)

ACME (Avg)

(AD)

Prop. mediated

0.08

(0.02 - 0.08)

0.05

Prop. mediated

(Cont)

(0.16 - 0.22)

0.19

Total effect

B. APOE ε4

(Avg)

(−0.05 - −0.01)

(−0.15 - −0.04)

−0.03

ADE (Avg)

(0.06 - 0.48)

ACME (Avg)

(AD)

Prop. mediated

0.19

0.28

(Cont)

(−0.18 - −0.07)

(0.12 - 0.55)

−0.13

95% CI

Prop. mediated

Est.

0.17
0.09

<2e-16
1.4e-03

0.02

0.11

0.07

0.19

0.20

−0.10

−0.03

0.16

0.24

−0.13

Est.

1.4e-03

1.4e-03

1.4e-03

<2e-16

8.0e-04

1.6e-03

8.0e-04

8.0e-04

8.0e-04

<2e-16

P-value

(0.06 - 0.14)

(0.14 - 0.2)

(0.01 - 0.03)

(0.07 - 0.17)

(0.04 - 0.11)

(0.16 - 0.22)

(0.1 - 0.4)

(−0.16 - −0.05)

(−0.04 - −0.01)

(0.07 - 0.37)

(0.13 - 0.43)

(−0.18 - −0.07)

95% CI

0.19
−0.01

<2e-16

0.00

<2e-16

<2e-16

−0.01

−0.01

<2e-16
<2e-16

0.18

−0.08

<2e-16

<2e-16

−0.13

0.01

1.2e-03

<2e-16

−0.06

−0.09

<2e-16

−0.12

<2e-16

Est.

<2e-16

P-value

(−0.07, 0.06)

(0.16 - 0.23)

(−0.01 - 0.01)

(−0.09 - 0.07)

(−0.05 - 0.03)

(0.16 - 0.22)

(−0.32 - 0.13)

(−0.19 - −0.07)

(−0.02 - 0.03)

(−0.25 - 0.1)

(−0.4 - 0.15)

(−0.18 - −0.07)

95% CI

8.1e-01

<2e-16

8.1e-01

8.1e-01

8.1e-01

<2e-16

4.3e-01

<2e-16

4.3e-01

4.3e-01

4.3e-01

<2e-16

P-value

Lipid score trained on combined AIBL and
ADNI (Healthy)

Lipid score trained on combined AIBL and
ADNI (Healthy)
Lipid score trained on BHS

All lipid species–based lipid scores

Concordant lipid species–based lipid scores

Mediation analysis of lipid species–based lipid scores for prevalent Alzheimer’s disease (AD) cases and APOE ε4 (A)/ε2 (B)

Total effect

A. APOE ε2

TA B L E 2

0.07

0.18

0.01

0.09

0.05

0.19

0.23

−0.10

−0.03

0.19

0.27

−0.13

(0.03 - 0.11)

(0.14 - 0.21)

(0.01 - 0.02)

(0.04 - 0.13)

(0.03 - 0.09)

(0.16 - 0.22)

(0.12 - 0.48)

(−0.15 - −0.04)

(−0.04 - −0.02)

(0.08 - 0.45)

(0.15 - 0.51)

(−0.18 - −0.07)

95% CI

Lipid score trained on BHS
Est.

<2e-16

<2e-16

<2e-16

<2e-16

<2e-16

<2e-16

<2e-16

2.8e-03

<2e-16

<2e-16

<2e-16

<2e-16

P-value

8
WANG ET AL .

9

WANG ET AL .

F I G U R E 4 Interaction of age on the associations of APOE ε4 with peripheral lipid species. Linear regression analyses of APOE ε4 against lipid
species, adjusted for APOE ε2, age, sex, BMI, total cholesterol, HDL-C, and triglycerides with the interaction terms of age (binary cut-off at
60-years-old, Panel A) was performed in the Busselton Health Study (BHS) cohort. Beta coefficients and 95% CI for each group were plotted (left
panels). Beta coefficients and 95% CI for lipid species showing significant interaction (P value < .05) are plotted together (right panel)

plasmalogens or alkyl diacylglycerol. APOE ε2 dramatically elevates

properties.27,33,34 Potentially the alkyldiacylglycerol species rather

the levels of both of these lipid classes, above those of typical phos-

represent sensitive markers of ether lipid synthesis or turnover per-

pholipid or triglyceride species. The APOE ε2 polymorphism may have

turbation. In contrast to APOE ε2, the APOE ε4 allele showed a weaker

selective preference for alkyldiacylglycerols and other ether lipids

association with lipid species, and those same species and the lipid

in incorporation into lipoproteins. Alternatively, the turnover rate of

scores mediated only a small proportion of the APOE ε4 risk on AD

lipoproteins with APOE variants has been highlighted previously, where

(7% and 9%, respectively), although here also the plasmalogen species

changes to the metabolic flux rate of lipoproteins due to their interac-

were the strongest mediators (Table 2; Figure S2; Table S12). This raises

tions with the low-density lipoprotein (LDL) receptor may influence its

the possibility that the two common polymorphisms of APOE mediate

composition.32 Although ether lipids are a diverse group of lipids, it is

risk through alternate mechanisms, with the resilient effect of APOE ε2

well known that plasmalogens represent the more biologically active

being more strongly influenced by its effect on ether lipid metabolism

lipid class, having been linked to anti-oxidative and anti-inflammatory

in the periphery.
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F I G U R E 5 Lipid species profiles significantly associated with apolipoprotein E (APOE) gene and prevalent Alzheimer’s disease (AD).
Meta-analysis of the Australian Imaging, Biomarkers and Lifestyle (AIBL) and Alzheimer’s disease Neuroimaging Initiative (ADNI) cohorts was
performed to identify lipid species associated with prevalent AD (linear regression of AD against lipid species, adjusted for APOE ε2, APOE ε4, age,
sex, BMI, total cholesterol, HDL-C, and triglycerides). Linear regression of APOE ε4 (A) or APOE ε2 (B) against lipid species, adjusted for age, sex,
BMI, total cholesterol, HDL-C, and triglycerides was performed in the in Busselton Health Study (BHS) cohort. The beta-coefficients for lipid
species significant in both analyses were plotted against each other. Dark closed circles highlight species that are in a concordant direction with ε4
risk increase (A) or ε2 risk reduction (B)

1.7

levels of these lipids in circulation and within immune cells.37 The

Next steps

use of alkyldiacylglycerol as a nutraceutical has been examined in
Our analyses demonstrate that up to 36% of the AD resilience asso-

the context of immune modulation38 and a potential treatment for spe-

ciated with APOE ε2 is mediated by lipid species (primarily ether

cific cancers,39 and the immune-modulating properties of ether lipids

lipids, alkyl diacylglycerol, and plasmalogen) and, to a lesser extent, the

has been reviewed.27,40

increased AD risk associated with APOE ε4 is also mediated by some

There is growing evidence of an immune component in AD

of the same lipid species. These lipid species then represent a potential

pathogenesis41 and genetic evidence linking both immunity and lipid

therapeutic target to reduce the risk of AD. However, it will be impor-

metabolism involvement with AD risk.42 The involvement of APOE in

tant to understand the mechanism(s) by which such ether lipids may

the immune response43,44 suggests that its potential role in risk reduc-

attenuate disease risk.

tion may be via modulation of immune cell function and behavior.

Alkyl diacylglycerol is a naturally occurring class of lipids, particu-

More recently, ether lipids have been linked directly to ferroptosis,45,46

and relatively

a novel cell death mechanism that links together immunity,47 iron

abundant in human breast milk,36 which, upon ingestion, can be metab-

metabolism, and AD.48,49 Plasmalogens, an end product of the ether

olized into plasmalogens and other ether lipid species, to increase the

lipid biosynthetic pathway resulting from the formation of the vinyl

larly enriched in the livers of several species of sharks35
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ether bond by the desaturase PEDS1/TMEM189, appear to play comferroptosis.45

Finally, although we were able to validate many of our analyses

Although our

across cohorts, the interaction of age with the association between

data do not directly link ferroptosis, APOE polymorphisms and AD

plasma lipid species and APOE variants requires external validation on

together, the critical role of ether lipids in mediating these biological

an independent cohort. The sample size and age range required meant

processes necessitates further examination. In vitro and in vivo stud-

that this effect could be explored only in the BHS cohort in this study.

plex and possibly contradicting roles in

ies exploring the role of ether lipids, ferroptosis, and immune cell function in the context of AD will likely provide some of the answers to the
mechanisms by which ether lipids may be mediating the risk reduction

1.9

Conclusion

afforded by APOE ε2.
With this insight, a next logical step would be to modulate ether

Here, we combine the power of two large clinical studies of AD with

lipid species with a view toward preventing or attenuating AD onset

an Australian population study to elucidate the relationship between

and progression, or to influence surrogate AD risk markers (Aβ, phos-

APOE variants and lipid metabolism. We demonstrate a strong rela-

phorylated tau, or cognition) in the early stages of disease. Modula-

tionship of APOE ε2 and ε4 alleles with ether lipid species. We fur-

tion of ether lipid species in humans has been demonstrated in sev-

ther demonstrate that these same lipid species strongly mediate the

eral

studies,31,37

where the biologically active precursor, alkylglyc-

erols, that can be synthesized50 or derived from natural sources in

resilient effects of APOE ε2 on AD risk, thereby presenting a therapeutic opportunity.

various marine animals27,51 has been used to bypass the rate-limiting
peroxisomal step to upregulate plasmalogen synthesis. Because the
vinyl-ether bond of plasmalogen species is highly susceptible to acid
hydrolysis, ingestion of these species may not be the optimal approach

2
PART 2–CONSOLIDATED RESULTS AND
STUDY DESIGN

to raise plasmalogen levels. Thus the non-plasmalogen precursors
may serve as better and more-stable dietary interventions for raising

2.1

Study design

plasmalogens.
The expected development of sporadic AD likely spans decades

This study includes three main sections of analyze (Figure 1). First, lipid

prior to the onset of symptoms52 ; therefore, early intervention will

association studies with APOE were performed using only the cogni-

be required. Nutraceuticals comprising alkyldiacylglycerols are poten-

tively healthy individuals to avoid any associations driven by reverse

tially low-cost, low-risk dietary supplements that may provide tangible

causation, whereas associations with AD prevalence were examined

risk reductions and so represent prime targets as a proactive preven-

between the CN and AD subsets. In BHS, interaction of APOE alleles

tative measure for AD. To demonstrate efficacy for such an interven-

and age was examined using a binary cut-off at 60 years (Table S5).

tion will require substantial investment in clinical trials of sufficient size

Next, associations between APOE genotypes and lipid species and

and duration to reach statistical significance. However, an additional

the associations between AD prevalence and lipid species were ana-

application of our findings is the development of these ether lipids as

lyzed using a fixed-effect inverse-variance weighted meta-analysis.

biomarkers to not only identify those at increased risk (for inclusion in

Heterogeneity between AIBL and ADNI was assessed using Cochran Q.

clinical studies) but also those who will most benefit from ether lipidmodulation therapy.

Then, the mediation analysis was performed on the aligned AIBL and
ADNI data sets to assess whether lipid species mediate the effects of
APOE on AD. We investigated two types of mediators: (1) individual
lipid species (which showed concordant associations with APOE and

1.8

Limitations and remaining questions

AD from the previous analyses) and (2) APOE lipid scores. The lipid
scores were created by ridge regression using either the lipid species

Our study examines the relationship between APOE polymorphisms

concordant in association with AD/APOE or all the lipid species to pre-

and plasma lipid species in the context of AD using three large inde-

dict APOE ε2/ε4. Causal mediation analysis was then performed to esti-

pendent cohorts. The classification of AD and non-AD dementia is clin-

mate the proportion of risk in the outcome model explained by a direct

ically difficult and is confirmed only through post-mortem examination.

effect of APOE genotype on prevalent AD and the proportion that was

Such misclassification could lead to confounding and underestimation

mediated by individual lipid species or lipid scores.

of effect sizes in our analyses. Further to this, in neurological diseases,
the importance of peripheral biomarkers remains contentious, as they
may not accurately reflect the neurological pathophysiology. However,

2.2

Results

there are many biological processes that can ultimately influence the
pathogenesis of neurological diseases, including the innate and adaptive immune systems. Additional research into lipid metabolic changes

2.2.1
The association of APOE genotypes with
plasma lipid species

within both the immune system and the brain, in relation to AD and
APOE variants, will shed light on the mechanisms by which dysregu-

In the BHS study, we observed 29 lipid classes and 347 lipid species

lated lipid metabolism may influence AD risk.

significantly associated with APOE ε2 after correction for multiple
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comparisons (Figure 2; Tables S1 and S2). Adjustment for clinical

and APOE ε2 (putative protective lipid species, Figure 4; Table S9).

lipids, to identify associations that are independent of lipoprotein

These lipid species included 37 species of ether phospholipids and 29

metabolism, resulted in 28 lipids classes and 237 lipid species signifi-

lipid species of sphingolipids, phosphatidylethanolamine, and dehydro-

cantly associated. There were 20 classes and 133 species associated

cholesterol species.

with APOE ε2 in the meta-analysis of the fully adjusted AIBL and ADNI

We observed fewer lipid species (24) showing concordant asso-

models. A total of 120 concordant lipid species from 18 lipid classes

ciations with AD and APOE ε4, which fall predominantly within the

including ceramide, hexosylceramide, sphingomyelin, plasmalogen,

ceramide, trihexosylceramide, alkenylphosphatidylethanolamine, and

alkyl diacylglycerol, and cholesteryl ester, were identified to be

lysophosphatidylethanolamine classes (Figure 4; Table S10).

nominally significant in both analyses.
A lower number of significant associations with APOE ε4 were
observed in both the BHS and meta-analysis of the AIBL and ADNI
cohorts. There were 23 lipid classes and 223 lipid species significantly

2.2.4
Mediating role of the plasma lipidome on the
effects of APOE on AD risk

associated with APOE ε4 in BHS, after correction for multiple comparisons (Figure S1; Tables S3 and S4). When we further adjusted

We identified 11 lipid species mediating the effect of APOE ε2 on

for clinical lipids, we observed 18 lipid classes and 104 lipid species

AD, after correcting for multiple comparisons (Figure S2; Table S11).

significantly associated with APOE ε4, after correction for multiple

These lipid species differed slightly from those mediating the effects

comparisons (Figure 2, Tables S3 and S4). Meta-analysis of the fully

of APOE ε4, largely comprising the alkyl phosphatidylcholine and phos-

adjusted models in the AIBL and ADNI cohorts identified only three

phatidylethanolamine and alkenyl phosphatidylethanolamine classes.

lipid species associated with APOE ε4, after correction. Ninety-one lipid

Of particular interest were three species of alkyldiacylglycerol TG

species were nominally significant, of which 43 species were also nom-

(O-50:1) [NL -16:0], TG (O-52:0) [NL -16:0], and TG (O-52:2) [NL -16:0],

inally significant in the BHS cohort.

which showed strong mediating effects, accounting for up to 30% of
the total effects of APOE ε2 on AD. There were 14 lipid species that
showed a significant mediation effect between APOE ε4 and AD, after

2.2.2
Interaction of age with the associations
between APOE and lipid species in the BHS cohort

correcting for multiple comparisons (Figure S2; Table S12). These lipid
species were of the dihydroceramide, alkylphosphatidylethanolamine,
and alkenylphosphatidylethanolamine classes.

We observed considerably stronger associations within the BHS

The APOE ε2 lipid scores derived from BHS and healthy AIBL/ADNI

cohort than the AIBL and ADNI meta-analysis, beyond that expected

both showed strong mediating effects on AD risk of 20% and 24%,

from the larger sample size. Owing to the larger age range of the

respectively (Table 2). In contrast, the mediating effects of the APOE ε4

BHS compared to the AIBL and ADNI cohorts, we hypothesized

lipid scores were smaller, but still significant, at 9% and 6% for the BHS

that age might influence how APOE genotype associates with plasma

and healthy AIBL/ADNI derived scores, respectively (Table 2). Media-

lipids. Interaction analysis with a binary cut-off at age 60 using the

tion analysis with lipid scores derived from all lipid species showed sim-

BHS cohort (age < 60, n = 2884; age ≥ 60, n = 1368) identi-

ilar performance when built using the BHS cohort, with a 23% and 7%

fied a nominal significant interaction of age with the association of

mediation effect for APOE ε2 and APOE ε4, respectively.

APOE ε2 with 48 lipid species from 12 classes (Figure 3, Table S6).
A greater number of the associations of APOE ε4 with lipid species
was observed to have interaction effects of age (88 lipid species

3

PART 3–DETAILED METHODS AND RESULTS

from 18 classes; Figure 4, Table S7). These included species of phosphatidylethanolamine, alkylphosphatidylethanolamine, alkenylphos-

More details of methodology including the data and statistical methods

phatidylethanolamine, and lysophosphatidylethanolamine. Of interest,

are described.

these results highlight weaker associations between lipid species and
APOE ε4 genotype with increasing age.

3.1
2.2.3
Concordance of the associations of APOE
alleles and prevalent AD with lipid species

3.1.1

Study cohorts
The Busselton Health study (BHS)

BHS is a community-based population study for which participants
We rationalized that lipids increased by the ε2 allele, but negatively

were recruited in Western Australia in the 1960s. The BHS holds

associated with AD may be involved in mediating risk reduction. Sim-

extensive phenotype data (eg, cardiovascular disease traits), high-

ilarly, lipids that associate in the same direction with AD and APOE ε4

density single-nucleotide polymorphism (SNP) panels, and plasma

are likely important in disease pathology. After aligning the associa-

lipidomic profiling data.53–55 In this study, we used data from 4492

tions of lipids species with AD (Table S8) and APOE ε2, we observed

participants who provided plasma samples at the 1994 to 1995

68 lipid species displaying an inverse association with AD diagnosis

recall.
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3.1.2
The Australian Imaging, Biomarkers and
Lifestyle (AIBL) flagship study

AD in ADNI followed the the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINDS-ADRDA) criteria,58 whereas

AIBL is a longitudinal study that initially recruited 1112 participants

the classification of MCI is defined according to the criteria proposed

who are older than 60 years of age. This included 768 cognitive nor-

by Petersen et al.59

mal individuals (CN), 133 with mild cognitive impairment (MCI), and
211 with AD at the last time point. The participants were recalled at
18-month intervals for up to 72 months. APOE genotype and other bio-

3.4

Statistical analysis

chemical data were collected. Lipidomics analysis was performed on all
available plasma samples, with 4106 fasted plasma samples examined

3.4.1

Cohort stratification

from baseline up to the fifth time point.56
We sought to examine the association of APOE genotypes with lipid
species independent of disease to avoid any associations driven by

3.1.3
(ADNI)

Alzheimer’s Disease Neuroimaging Initiative

reverse causation. Thus we utilized only the cognitively healthy individuals in the AIBL and ADNI cohorts. After removing samples with missing records, we had a total of 5284 participants: AIBL (n = 693), ADNI

ADNI is a multi-site longitudinal study using a non-randomized, natu-

(n = 207), and BHS (n = 4384). The characteristics of each cohort are

ral history, non-treatment design. The first phase (ADNI-1), launched

presented in Table 1. All the lipid species were log10 transformed, fol-

in 2004, aimed to track disease progression using biomarkers and to

lowed by normalization to zero mean and one-unit standard deviation.

identify features of MCI that may predict cognitive decline. Clinical
follow-up is available for up to 2 to 3 years post screening in the ADNI1 study, with participants carried forward into subsequent ADNI2-GO
studies. The ADNI-1 cohort includes 819 participants (229 CN, 398

3.4.2
species

Association of APOE genotypes with lipid

MCI, and 192 AD). Lipidomics was performed on all participants with
The associations between APOE genotype (ε2 and ε4) and lipid species

available samples at baseline.

were determined by linear regression in healthy individuals in each
cohort separately. BHS is a population cohort with voluntary enrolment

3.1.4

Ethics approval and consent to participate

and a median age of 48; we treated the BHS population as non-AD.
Adjustment for covariates and meta-analyses are described in Figure 1.

For all the above cohorts, written informed consent was obtained from
all participants before protocol-specific procedures were performed.

3.4.3
3.2
Lipid extraction and mass spectrometry
analysis

Identifying concordant associations with AD

Linear regression was used to determine the associations between lipid
species and AD, relative to healthy control. To identify associations
independent of APOE genotype, these analyses were adjusted for both

Extensive details on the lipidomic profiling of the BHS, ADNI, and

APOE ε2 and ε4. Other covariates included age, sex, BMI, and clinical

AIBL cohorts have been published previously.16,26,55 Lipid extractions

lipids. We then selected the lipid species that were associated with

were performed on plasma (AIBL) and serum (ADNI, BHS) samples as

both AD and APOE genotype (ε2 or ε4).

Lipidomic profiling (569 lipid species from 32

To identify lipids of potential biological relevance, we highlighted

classes) was carried out using scheduled multiple reaction monitoring

lipid species that were concordant in their association with APOE and

on an Agilent 6490 QqQ mass spectrometer.57

AD. Concordant species between APOE ε2 and AD were negatively

described

previously.57

associated with APOE ε2 but positively associated with AD, and vice
versa. Conversely, concordant species between APOE ε4 and AD were

3.3

positively or negatively associated with both APOE ε4 and AD.

Definition of AD state

In AIBL, clinical criteria used to determine disease status included
a Mini Mental State Examination score of <28, failure on the Logical Memory test, other evidence of possible significant cognitive diffi-

3.4.4
Mediation of the APOE genotype effect on
AD by lipid species

culty on neuropsychological testing, a Clinical Dementia Rating score
of ≥0.5, a medical history suggestive of the presence of illnesses likely

To assess whether lipid species mediate the effect of APOE on AD, we

to impair cognitive function, and an informant or personal history sug-

performed mediation analysis (using the R package “mediation”) on the

gestive of impaired cognitive

function.56

The definition of possible

combined AIBL and ADNI data sets (n = 1597). The analysis was con-
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ducted using either individual lipid species that showed concordant

AG046171, RF1 AG051550, RF1 AG057452, and 3U01 AG024904-

associations with APOE and AD, or lipid scores for APOE genotypes.

09S4). Additional United States National Institutes of Health (NIH)

Two lipid scores (Figure 1, lower panel) were created by ridge regres-

support from the NIA, National Library of Medicine (NLM), and

sion (R package “glmnet”) using either: (1) the lipid species concordant

National Cancer Institute (NCI) for analysis includes P30 AG10133,

in association with AD/APOE; or (2) all lipid species. Penalty param-

R01 AG19771, R01 LM012535, R03 AG054936, R01 AG061788,

eters were optimized using internal 10-fold cross-validation. As illus-

K01 AG049050, and R01 CA129769. Matthias Arnold is supported

trated in Figure 1 (lower panel), models were created using the BHS

by NIA grants RF1 AG057452, RF1 AG058942, RF1 AG059093, and

cohort (n = 4384) or the combined AIBL and ADNI cohorts (healthy

U01 AG061359. Matthias Arnold is also supported by funding from

individuals; n = 900), adjusting for age, sex, BMI, fasting status, HDL-C,

Qatar National Research Fund NPRP8-061-3-011. Kwangsik Nho is

total cholesterol, and triglycerides. The resulting predicted values on
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the whole population of combined AIBL and ADNI cohorts (n = 1597)

lection and sharing for the Alzheimer’s Disease Neuroimaging Initiative
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ation analysis.

by the National Institute on Aging, the National Institute of Biomedical

Causal mediation analysis (Figure 1, lower panel) was performed

Imaging and Bioengineering, and through generous contributions
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scores, adjusting for the same covariates. Causal mediation analysis
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